...
首页> 外文期刊>Journal of Biotechnology >Generation of HIV-1 Gag VLPs by transient transfection of HEK 293 suspension cell cultures using an optimized animal-derived component free medium
【24h】

Generation of HIV-1 Gag VLPs by transient transfection of HEK 293 suspension cell cultures using an optimized animal-derived component free medium

机译:通过使用优化的动物衍生无组分培养基瞬时转染HEK 293悬浮细胞培养物来生成HIV-1 Gag VLP

获取原文
获取原文并翻译 | 示例

摘要

Virus-like particles (VLPs) offer great promise as candidates for new vaccine strategies. Large-scale approaches for the manufacturing of HIV-1 Gag VLPs have mainly focused on the use of the baculovirus expression system. In this work, the development and optimization of an HIV-1 Gag VLP production protocol by transient gene expression in mammalian cell suspension cultures is reported. To facilitate process optimization, a Gag-GFP fusion construct enabling the generation of fluorescent VLPs was used. The great majority of Gag-GFP present in cell culture supernatants was shown to be correctly assembled into virus-like particles of the expected size and morphology consistent with immature HIV-1 particles. Medium optimization was performed using design of experiments (DoE). Culture medium supplementation with non-animal derived components including recombinant proteins and lipids of synthetic or non-animal-derived origin resulted in improved HEK 293 cell growth and VLP production. The maximum cell density attained using the optimized Freestyle culture medium was 5.4 x 10(6) cells/mL in batch mode, almost double of that observed using the unsupplemented medium (2.9 x 10(6) cells/mL). Best production performance was attained when cells were transfected at mid-log phase (2-3 x 10(6) cells/mL) with medium exchange at the time of transfection using standard amounts of plasmid DNA and polyethylenimine. By using an optimized production protocol, VLP titers were increased 2.4-fold obtaining 2.8 mu g of Gag-GFP/mL or 2.7 x 10(9) VLPs/mL according to ELISA and nanoparticle tracking quantification analyses, respectively
机译:病毒样颗粒(VLP)可作为新疫苗策略的候选物。制造HIV-1 Gag VLP的大规模方法主要集中在杆状病毒表达系统的使用上。在这项工作中,报道了通过在哺乳动物细胞悬浮培养物中瞬时基因表达来开发和优化HIV-1 Gag VLP生产方案。为了促进工艺优化,使用了能够产生荧光VLP的Gag-GFP融合构建体。细胞培养上清液中存在的绝大多数Gag-GFP已被正确组装成预期大小和形态与未成熟HIV-1颗粒一致的病毒样颗粒。使用实验设计(DoE)进行培养基优化。用非动物来源的成分(包括重组蛋白和合成或非动物来源的脂质)补充培养基可改善HEK 293细胞的生长和VLP的产生。在分批模式下,使用优化的Freestyle培养基可获得的最大细胞密度为5.4 x 10(6)个细胞/ mL,几乎是使用未添加培养基所观察到的最大细胞密度(2.9 x 10(6)个细胞/ mL)。当使用标准量的质粒DNA和聚乙烯亚胺在转染时以对数中期(2-3 x 10(6)细胞/ mL)转染培养基并进行培养基交换时,获得了最佳的生产性能。通过使用优化的生产方案,根据ELISA和纳米颗粒跟踪定量分析,分别将VLP滴度提高了2.4倍,获得2.8μg Gag-GFP / mL或2.7 x 10(9)VLP / mL

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号